Be Biopharma Funding & Investors
Cambridge, MA
Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
be.bioTotal Amount Raised: $182,000,000
Be Biopharma Funding Rounds
Series B
$130,000,000
Series B Investors
Arch Venture PartnersTakeda VenturesLongwood FundRa Capital ManagementAlta PartnersAtlas VentureBristol-Myers SquibbSeries A
$52,000,000
Series A Investors
Atlas VentureRa Capital ManagementTakeda VenturesLongwood FundAlta Partners
Funding info provided by Diffbot.